Welcome to the News You Might Have Missed, a weekly roundup of psychedelic medicine headlines to help you catch up and stay informed. It was a busy week with lots of news, have a look and see you next week for another update.
Cathie Wood’s ARK Fund Buys More Atai Stock
Following up on last week’s reporting, ARK investor Cathie Wood has made another significant investment in Atai. This time Wood’s ARK innovation fund has bought 285,454 shares of Atai stock, for an approximate value of $1.1 million.
Since last week’s buy-in of 100,000+ shares, the fund has made 4 other purchases, bringing its total investment for the month of July to 621,812 shares.
PharmaTher Granted Patent For Ketamine and Parkinson’s
Fabio Chianelli, CEO of PharmaTher: “The US Notice of Allowance of the Patent Application not only adds to our intellectual property portfolio covering novel uses, delivery forms and formulations of ketamine, but it also strengthens our commercial opportunities with ketamine as a potential treatment for Parkinson’s disease and movement disorders. We are focused on advancing a potential Phase 3 clinical study for ketamine in the treatment of levodopa-induced dyskinesia in patients with Parkinson’s disease.”
Numinus Wellness Inc. Reports Q3 2022 Results
“Our fiscal third quarter was highlighted by the announcement of our acquisition of Novamind, and the activities leading up to the completion of that strategic transaction on June 10, 2022. Now, with 13 wellness clinics across North America, four clinical research sites and a dedicated psychedelics research facility, Numinus is firmly positioned as a leading mental health care company providing psychedelic-assisted therapies.” said Payton Nyquvest, Founder and CEO.
- Revenues grew 32% year-over-year to $0.74 million for the quarter
- Clinic network revenues grew 59.5% from the same quarter last year and 7.5% compared to prior quarter
- Achieved 24.4% gross margin and $180,845 gross profit of during Q3 2022
- Ended quarter with strong cash position of $41.8 million
- Completed acquisition of Novamind, positioning Numinus as a leading, integrated mental healthcare company providing psychedelic-assisted therapies
Filament Health Issued Its Third US Patent
Filament Health has been issued a third patent by the United States Patent and Trademark Office for the extraction of natural psilocybin and associated psychedelic compounds.
“The continued growth of Filament’s American patent portfolio is a testament to the strength of our drug development platform,” said Benjamin Lightburn, Chief Executive Officer. “This approval represents the viability of our IP strategy in the US in addition to our success in Canada.”
Awakn Life Sciences Provides a Business and Corporate Update
The update includes information on Awakn’s patent program, personnel changes, and deals with multiple clinics in North America.
Awakn CEO, Anthony Tennyson, commented, “We are delighted to see our Licensing Partnerships business move into its ‘Beta’ phase as we execute on our strategy of commercializing our therapeutics. I would also like to thank Kate Butler for all her work with Awakn and wish her the very best in her next venture.”
